- Apollomics (NASDAQ:APLM) has announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as changes to its executive leadership team.
- As a result of the updated strategic focus, and aligned with the Co.’s resource needs going forward, Sanjeev Redkar, Ph.D., Co. co-founder and President, and Peony Yu, M.D., CMO, are expected to transition to consulting roles in August.
- “We believe that the target selectivity and efficacy of vebreltinib against multiple tumor types demonstrates its high potential to treat a range of MET-altered tumors,” said Guo-Liang Yu, Ph.D., Chairman and CEO.
- Apollomics now expects that its current capital resources will fund planned operations into the third quarter of 2025.
- APLM +5.25% premarket to $0.2023.
2024-07-03